Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
We're hiking our GEHC price target, looking beyond a mixed quarter to next year's catalysts
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
McDonald's executives say E. coli outbreak is 'behind us'
23andMe appoints three new board members following abrupt resignations
Oracle announces new AI-powered electronic health record
Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
